Abstract: Provided is use of kinin or derivative thereof, in particular long-acting kinin or derivative thereof, in treating vascular cognitive impairment (VCI), post-stroke cognitive impairment (PSCI), or cerebral small vessel disease (CSVD). VCI and PSCI are generally associated with cognitive function impairment and psychoactive behavioral symptom. Drugs for treating cognitive impairment in VCI and PSCI include cholinesterase inhibitors, non-competitive N-methyl-D-asparagine receptor antagonists, and drugs for treating psychoactive behavioral symptom include antidepressants. Patients with chronic CSVD may have symptoms such as cognitive disorder, movement disorder, emotional disorder, defecation disorder and other symptoms. Cholinesterase inhibitors and non-competitive N-methyl-D-asparagine receptor antagonists can be used for cognitive disorder, and antidepressants are generally used for depression.

Abstract: Apparatus having an array of memory cells and a controller for access of the array of memory cells, wherein the controller is configured to cause the apparatus to apply a reference current to a selected access line, determine a time difference between a voltage level of a near end of the selected access line being deemed to exceed a first voltage level while applying the reference current and the voltage level of the near end of the selected access line being deemed to exceed a second voltage level while applying the reference current, and determine a capacitance value of the selected access line in response to a current level of the reference current, the time difference, and a voltage difference between the second voltage level and the first voltage level.

Abstract: Disclosed is a method for preparing a product for treating scald infection caused by Pseudomonas aeruginosa. The product includes a ferrous sulfate hydrogel, the scald is a deep second-degree scald or a third-degree scald, and a preparation process of the ferrous sulfate hydrogel includes: S1, obtaining a mixed solution by dissolving ferrous sulfate and vitamin C at a concentration ratio of 1:1 in sterile ultrapure water, heating the mixed solution to 50° C., and a concentration of the ferrous sulfate in the mixed solution being 2 mM, and S2, under a condition of heating, continuing to add sodium alginate powder whose mass constitutes 3.5% of a total mass of the mixed solution, stirring until the sodium alginate powder is dissolved and forming a stable colloid, and obtaining 2 mM of the ferrous sulfate hydrogel.

Abstract: Provided is a method for calibrating a deformation pressure of a large-volume press. The method for calibrating the deformation pressure of the large-volume press includes: depositing a conductive layer onto a surface of a bevel plug to obtain a conductive bevel plug; assembling the conductive bevel plug, a molybdenum pillar, a magnesium oxide tube, a magnesium oxide sample chamber, a magnesium oxide octahedron and a calibration standard material, placing a resulting system in the large-volume press, and subjecting the resulting system to a large-volume press pressure correction experiment.

Abstract: Disclosed are a method and a device for identifying full-section excavation parameters of large-section tunnel with broken surrounding rock, which is capable of solving the problem of inaccurate arrangement of blasting hole points in tunnel excavation engineering, including following steps: establishing a three-dimensional finite element model based on a blasting section design of a tunnel; performing a simulation with the three-dimensional finite element model based on blasting design parameters to obtain blasting quality parameters; selecting a group closest to a preset quality parameter from multiple groups of the blasting design parameters as target blasting design parameters, wherein the preset quality parameter is an acceptance grade standard of the tunnel; obtaining first thermal imaging information of a first hot spot of a surface to be blasted; calibrating actual hole spacing parameters based on the first thermal imaging information and the target blasting design parameters.

Abstract: Provided in the invention are a catalyst for preparing phosgene and a preparation method therefor, and a method for the preparation of phosgene and the comprehensive utilization of energy thereof. The preparation method comprises the following steps: 1) stirring and soaking activated carbon in a modifying solution, then adding dimethyltin dichloride and chromium oxide powders and carrying out a reaction, and then adding a nickel oxide fine powder and ultrasonically oscillating same to prepare a pre-modified activated carbon; 2) drying the pre-modified activated carbon; and 3) heating and calcinating the dried pre-modified activated carbon from step 2) to prepare the catalyst.

Abstract: Disclosed is a method for preparing a product for treating scald infection caused by Pseudomonas aeruginosa. The product includes a ferrous sulfate hydrogel, the scald is a deep second-degree scald or a third-degree scald, and a preparation process of the ferrous sulfate hydrogel includes: S1, obtaining a mixed solution by dissolving ferrous sulfate and vitamin C at a concentration ratio of 1:1 in sterile ultrapure water, heating the mixed solution to 50° C., and a concentration of the ferrous sulfate in the mixed solution being 2 mM, and S2, under a condition of heating, continuing to add sodium alginate powder whose mass constitutes 3.5% of a total mass of the mixed solution, stirring until the sodium alginate powder is dissolved and forming a stable colloid, and obtaining 2 mM of the ferrous sulfate hydrogel.

Abstract: A pharmaceutical combination comprising (i) a first component selected from an immune effector cell (e.g., a T cell and an NK cell) expressing a molecular switch-regulated CAR polypeptide, a nucleic acid molecule encoding the CAR polypeptide, a vector comprising the nucleic acid molecule, and any combination thereof; and (ii) a second component, which is an antibody that contains a P329G mutation and specifically binds to a B-cell maturation antigen (BCMA) protein. The present invention also relates to a kit comprising the pharmaceutical combination, and the use of the pharmaceutical combination in the treatment of BCMA-related diseases in a subject.

Abstract: Provided is an information system and an information collection method that are capable of acquiring desired site data while preventing an increase in cost. A link logic definition unit 17 holds a link logic that is definition information defining a correspondence relation between an item value of the site data and a reference value that is an external value of transaction data used for acquiring the item value. A link logic data acquisition unit 18 acquires the item value of the site data by using the link logic.

Abstract: Provided are an antibody having an improved affinity for specifically binding to BCMA, an antibody further comprising a P329G mutation, and a conjugate, a fusion, a bispecific antibody or a pharmaceutical composition comprising the antibody. In addition, further provided are a nucleic acid encoding the antibody, a host cell comprising the nucleic acid, and a method for preparing the antibody. The present invention also relates to the therapeutic and diagnostic use of the antibody binding to BCMA.

Abstract: The present disclosure provides a method, apparatus, medium and device for extracting a river drying-up region and frequency, and belongs to the technical field of remote sensing. The method for extracting a river drying-up region and frequency can be applied to efficiently acquiring river drying-up information for a long time within the large spatial region. With the inverse normalized difference water index (iNDWI) and the maximum value composite (MVC) method for the remote sensing images, the present disclosure omits the troublesome step of separately extracting a river range for each image in the conventional method. In addition, the present disclosure quickly obtains the drying-up frequency by counting the total number of available images and the number of non-water images at the same pixel position, and yields a greater efficiency for extracting the river drying-up region and frequency.

Abstract: The present invention provides a mono-p-toluenesulfonate of (S)-(2-((5-chloro-2-((7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-5-(methoxymethyl)phenyl)dimethyl phosphine oxide, and a hydrate and a crystal form thereof. The crystal form of p-toluenesulfonate has a good stability, is easy to process, and has a high solubility.

Abstract: Memory array structures might include a first conductive plate connected to memory cells of a first dummy block of memory cells and to memory cells of a second dummy block of memory cells on opposing sides of a first isolation region; a second conductive plate connected to memory cells of the first dummy block of memory cells and to memory cells of the second dummy block of memory cells on opposing sides of a second isolation region; first and second conductors selectively connected to a first global access line, and connected to the first conductive plate on opposing sides of the first isolation region; third and fourth conductors selectively connected to a second global access line, and connected to the second conductive plate on opposing sides of the second isolation region; and a fifth conductor connected to the third conductor and connected to the second conductor.

Abstract: The present invention generally relates to humanized antigen binding receptors capable of specific binding to an Fc domain comprising the amino acid mutation P329G according to EU numbering. The present invention also relates to T cells, transduced with an antigen binding receptor which is recruited by specifically binding to/interacting with the mutated Fc domain of therapeutic antibodies.

Abstract: A memory device includes a memory array configured as quad-level cell (QLC) memory and a control logic operatively coupled to the memory array. The control logic identifies a first two bits of particular pages of a QLC logical state. The control logic causes memory cells of the memory array to be coarse programmed with a threshold voltage distribution of a multi-level cell (MLC) logical state corresponding to the first two bits. The control logic reads the MLC logical state from the memory cells and a second two bits from a cache buffer to determine the QLC logical state. The control logic causes the memory cells to be further coarse programmed with a QLC threshold voltage distribution corresponding to the QLC logical state.

Abstract: The present invention relates to macrocyclic compounds of any one of Formula (I), or a pharmaceutically acceptable form thereof, pharmaceutical compositions comprising the same, methods of preparing the same, and methods of treating cancer dependent on a farnesylated protein, using the same.

Abstract: A consensus method for a blockchain includes: obtaining, in a consensus reaching process of a block initiated by a proposal node, prevote messages generated by consensus nodes in a blockchain network; counting a quantity of first prevote messages for the block based on the received prevote messages, the first prevote messages being generated by the consensus nodes within a set duration in response to a proposal message for the block, the set duration corresponding to the proposal node and being determined based on a block generation duration of the proposal node; and adjusting the set duration corresponding to the proposal node recorded by the consensus nodes based on the quantity of the first prevote messages.

Abstract: The present invention provides a methionine adenosyltransferase 2A inhibitor. The structure of the methionine adenosyltransferase 2A inhibitor is as represented by general formula (I), and the definitions of substituents are as described in the specification. The present invention further provides a preparation method therefor. A compound represented by formula I provided by the present invention has significant methionine adenosyltransferase 2A inhibitory activity, and can be used in the treatment of diseases mediated by overexpression of methionine adenosyltransferase 2A.

Abstract: The present disclosure discloses a Bluetooth communication method having automatic re-connection activating mechanism that includes steps outlined below. A first broadcast signal is transmitted by an electronic device such that a smart device receives and identifies the electronic device as a terminal device. An initial connection is established and pairing is performed with the smart device by the electronic device such that the smart device stores device related information of the electronic device. A second broadcast signal is transmitted by the electronic device such that the smart device receives the second broadcast signal and identifies the electronic device according to the device related information to further activate an auto-connection application program according to positioning beacon information included in the second broadcast signal.

Abstract: A Bluetooth low energy mesh network system includes a transmission controller circuit and a host controller circuit. The transmission controller circuit is configured to determine whether an advertising packet comprises a message associated with a Bluetooth low energy mesh network. The host controller circuit is configured to be woke up from a sleep mode in response to a report from the transmission controller circuit when the transmission controller circuit determines that the advertising packet comprises the message, in order to transmit the message to an application layer.